Lifeboat Foundation

Washington state is experiencing its first known outbreak of a potentially deadly fungus, according to public health officials.

Four patients in the last month have tested positive for Candida auris, or C. auris, Public Health — Seattle & King County said in a release.

The first case occurred in a patient who had recently been admitted to Kindred Hospital Seattle, which was identified through a proactive screening program.

SpaceX will become the co-owner of valuable data, biological samples, and possibly even patents and intellectual property related to human spaceflight, according to the terms and conditions of a new program inviting research on crewed Dragon missions.

The company started quietly inviting proposals “for exceptional science and research ideas that will enable life in space and on other planets,” to be executed on orbit using its Dragon spacecraft capsule. Specifically, SpaceX says it’s looking for research studies and experiments focused on fitness, or solutions to increase “efficiency and effectiveness,” and those focused on human health during long-duration spaceflight missions.

Selected research study groups would have access to SpaceX’s crewed Dragon missions, opening up a whole new use case for one of the company’s core products.

A team of molecular engineers have developed a type of plastic that can be shape-shifted using tempering. In their paper published in the journal Science the team, from the University of Chicago, with a colleagues from the US DEVCOM Army Research Laboratory, Aberdeen Proving Ground, the National Institutes of Standards and Technology and the NASA Glenn Research Center, describe how they made their plastic and how well it was able to shape shift when they applied various types of tempering.

Haley McAllister and Julia Kalow, with Northwestern University, have published a Perspective piece in the same issue of Science outlining the work.

Over the past several years, it has become evident that the use of plastics in products is harmful to not only the environment but also human health —bits of plastic have been found in the soil, the atmosphere, the oceans, and the human body.

A gene editing tool using a system known as CRISPR-Cas9 has recently been approved by the U.S. Food and Drug Administration (FDA) for sickle cell disease. The drug is known as Casgevy and the media has hailed this treatment as a ‘cure’ for sickle cell anemia patients. While it is still unclear if the drug completely cures these patients, clinical trials show exciting efficacy.

Sickle cell disease is a genetic blood disorder affecting thousands of US citizens. Many of these patients are African American and Hispanic. In sickle cell disease, hemoglobin, a protein in red blood cells that helps carry oxygen throughout the body, is mutated. As a result, blood cells change shape in the form of a sickle, giving the disease its name. Unfortunately, the mutated cells cause disruption of blood flow and prevent other blood cells from delivering oxygen to the body. This disease is extremely rare and can lower the quality of life in patients. Previously, there were limited treatments options including transfusions and medications for pain management. However, Casgevy provides a new option to help treat the patient and relieve pain for over a year after a single treatment.

One-time treatment using Casgevy improved life quality for sickle cell patients. A single-arm trial was conducted at multiple health centers in adults and adolescents. These patients were screened for two vaso-occlusive crises (VOCs) which are described as severely painful events due to a lack of oxygen delivery from sickle cell blood cells blocking blood flow. The primary measure of success in the trial was the number of VOCs after treatment. In total, 44 patients received Casgevy and 33 were able to follow up and be evaluated. Of the 33 patients that made it through the trial, 29 of them did not experience any VOCs for 12 months. This is a 93.5% success rate based on the number of patients that were analyzed. All 44 patients were able to successfully undergo treatment without any graft rejection. In addition, researchers concluded that this treatment was not only effective, but safe with few side effects.

Our very old immune systems can’t keep up with modern lifestyles and diets, leading to increases in all sorts of chronic health problems like allergies and obesity.

Hybrid Intelligence, an emerging field at the intersection of human intellect and artificial intelligence (AI), is redefining the boundaries of what can be achieved when humans and machines collaborate. This synergy leverages the creativity and emotional intelligence of humans with the computational power and efficiency of machines. Let’s explore how hybrid intelligence is augmenting human capabilities, with real examples and its impacts on the human workforce.

Hybrid intelligence is not just about AI assisting humans; it’s a deeper integration where both sets of intelligence complement each other’s strengths and weaknesses. While AI excels in processing vast amounts of data and pattern recognition, it lacks the emotional intelligence, creativity, and moral reasoning humans possess. Hybrid systems are designed to capitalize on these respective strengths, leading to outcomes that neither could achieve alone.

In the healthcare sector, hybrid intelligence is enhancing diagnostic accuracy and treatment efficiency. IBM’s Watson Health, for example, assists doctors in diagnosing and developing treatment plans for cancer patients. By analyzing medical literature and patient data, Watson provides recommendations based on the latest research, which doctors then evaluate and contextualize based on their professional judgment and patient interaction.

In today’s column, I am continuing my ongoing series about the impact of generative AI in the health and medical realm.

You can use generative AI to analyze your sleeping dreams, but do so with caution and a keen eye. This close up look tells you how to best proceed.

Tedros Adhanom Ghebreyesus, director-general of the World Health Organization (WHO), will be joined by policymakers and members of the health industry to consider how to prepare for the emergence of an unknown pathogen.

Michel Demaré, chair of the board of pharmaceutical giant AstraZeneca, Brazilian health minister Nisia Trindade Lima and two other executives will also be on the panel, as will Shyam Bishen, a New York-based healthcare executive and member of the WEF’s executive committee.

He told CNBC on Monday that the forum had calculated that preparing the global health system for another pandemic would require “close to a trillion dollars,” describing the topic as a “big question.”

The US is dealing with an “out-of-control” epidemic of sexually transmitted infections, according to the National Coalition of STD Directors.

The warning comes after the release of an annual data report on STIs by the US Centers for Disease Control and Prevention (CDC).

The exasperation of public health officials can be felt in the very first sentence of the online announcement.